• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by CareDx Inc.

    5/6/25 5:00:40 PM ET
    $CDNA
    Medical Specialities
    Health Care
    Get the next $CDNA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001180466
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    CareDx, Inc.
    SEC File Number
    001-36536
    Address of Issuer
    8000 Marina Boulevard
    4th Floor
    Brisbane
    CALIFORNIA
    94005
    Phone
    1-415-287-2300
    Name of Person for Whose Account the Securities are To Be Sold
    Christine M. Cournoyer
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Goldman Sachs & Co. LLC
    200 West Street
    New York � NY � 10282
    167002533395568054905/06/2025
    NASD


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common04/01/2021Acquired as compensation -- Restricted Stock UnitsIssuerCheckbox not checked441304/01/2021Compensation
    Common06/16/2024Acquired as compensation -- Restricted Stock UnitsIssuerCheckbox not checked1228706/16/2024Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    05/06/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Goldman Sachs & Co. LLC on behalf of Christine M. Cournoyer

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CDNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDNA

    DatePrice TargetRatingAnalyst
    1/15/2025$28.00 → $24.00Underweight → Equal Weight
    Wells Fargo
    8/28/2024$28.00Underweight
    Wells Fargo
    8/19/2024$40.00Neutral → Buy
    BTIG Research
    5/13/2024Outperform → Mkt Perform
    Raymond James
    5/1/2024$15.00Hold → Buy
    Craig Hallum
    11/9/2023$10.00Equal-Weight → Overweight
    Stephens
    8/15/2023$12.00Mkt Perform → Outperform
    Raymond James
    5/11/2023Buy → Neutral
    BTIG Research
    More analyst ratings

    $CDNA
    Financials

    Live finance-specific insights

    See more
    • CareDx to Report First Quarter 2025 Financial Results

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-445-7795 for domestic callers or 1-785-424-1699 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, please

      4/8/25 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx to Report Fourth Quarter and Full Year 2024 Financial Results

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2024 after market close on Wednesday, February 26, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-267-6316 for domestic callers or 1-203-518-9783 for international callers. Please reference Conference ID: CareDx. To listen to

      2/11/25 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Reports Preliminary Financial Results for Third Quarter 2024

      Third Quarter 2024 Financial Results to be Reported on November 4, 2024 CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers —today reported preliminary financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Third quarter revenue is expected to be in the range of $82 million to $83 million, an increase of approximately 23% year-over-year. Grew Testing Services volume to approximately 44,600, an increase of approximately 16% year-over-year. Testi

      10/15/24 6:00:00 AM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CareDx Reports First Quarter 2025 Results

      First Quarter Revenue of $84.7 Million, Increased 18% Year-Over-Year Grew Testing Services Volume to Approximately 47,100, Marking Seventh Consecutive Quarter of Sequential Testing Services Volume Growth CareDx, Inc. (NASDAQ:CDNA) today reported financial results for the first quarter ended March 31, 2025. First Quarter Financial Highlights Reported first quarter revenue of $84.7 million, increased 18% year-over-year Testing services revenue of $61.9 million, increased 15% year-over-year, and testing services volume of approximately 47,100, increased 12% year-over-year GAAP net loss of $10.4 million, non-GAAP net income of $5.4 million, and positive adjusted EBITDA of $4.6 million,

      4/30/25 4:05:00 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ ("CareDx" or the "Company")— a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 7, 2025, CareDx granted to Jennifer Foley, the Company's newly appointed Chief Product Officer, certain stock awards as an inducement material to Ms. Foley's employment with CareDx. CareDx granted Ms. Foley 36,231 restricted stock units ("RSUs") pursuant to the Company's 2016 Inducement Equity Incentive Plan, which was approved by the Compensation Committee of the Company's Board o

      4/21/25 4:01:00 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx to Report First Quarter 2025 Financial Results

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by dialing 1-800-445-7795 for domestic callers or 1-785-424-1699 for international callers. Please reference Conference ID: CareDx. To listen to the webcast, please

      4/8/25 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CareDx Inc.

      SC 13G/A - CareDx, Inc. (0001217234) (Subject)

      11/14/24 5:13:57 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CareDx Inc.

      SC 13G/A - CareDx, Inc. (0001217234) (Subject)

      11/8/24 2:34:10 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CareDx Inc.

      SC 13G/A - CareDx, Inc. (0001217234) (Subject)

      11/5/24 6:07:26 AM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cournoyer Christine sold $235,929 worth of shares (16,700 units at $14.13), decreasing direct ownership by 31% to 37,045 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      5/8/25 4:31:15 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Secretary and General Counsel Novack Jeffrey Adam sold $39,514 worth of shares (2,688 units at $14.70), decreasing direct ownership by 2% to 121,350 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      5/7/25 4:38:39 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • Secretary and General Counsel Novack Jeffrey Adam covered exercise/tax liability with 2,873 shares, decreasing direct ownership by 2% to 124,038 units (SEC Form 4)

      4 - CareDx, Inc. (0001217234) (Issuer)

      5/5/25 4:53:42 PM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Leadership Updates

    Live Leadership Updates

    See more
    • CareDx Appoints Jing Huang Chief Data and AI Officer

      CareDx, Inc. (NASDAQ:CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the appointment of Jing Huang Ph.D., in the newly created role of Chief Data and Artificial Intelligence (AI) Officer. Huang will lead key data science initiatives that are a part of the Company's long-term strategic growth plan. CareDx intends to share its long-term growth strategy during an Investor Day on October 15, 2024. Huang is a recognized leader in data science and machine learning, bringing to CareDx a proven trac

      10/9/24 7:05:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer

      CareDx Announces Addition of Operational and Commercial Expertise to Lead Key Strategic Initiatives Marica Grskovic Appointed Chief Strategy Officer to Lead Corporate Development CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the appointment of two senior executives who will lead key initiatives as the Company advances its long-term strategic growth plan. CareDx will be sharing its long-term growth strategy during an Investor Day in October 2024. Keith Kennedy brings more than 20 years of experience and e

      9/12/24 7:01:00 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Appoints John W. Hanna as its New President and Chief Executive Officer

      CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company's Board of Directors, effective April 15, 2024. "John is an outstanding leader with a proven track record of building high-performing teams that deliver consistent results. With extensive experience in the molecular diagnostics and life sciences tools industries, John is the right executive to bring strategic leadership to CareDx to propel the compan

      4/16/24 4:02:00 PM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    SEC Filings

    See more
    • SEC Form 144 filed by CareDx Inc.

      144 - CareDx, Inc. (0001217234) (Subject)

      5/6/25 5:00:40 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by CareDx Inc.

      10-Q - CareDx, Inc. (0001217234) (Filer)

      4/30/25 4:18:38 PM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CareDx, Inc. (0001217234) (Filer)

      4/30/25 4:11:42 PM ET
      $CDNA
      Medical Specialities
      Health Care

    $CDNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CareDx upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded CareDx from Underweight to Equal Weight and set a new price target of $24.00 from $28.00 previously

      1/15/25 7:29:19 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • Wells Fargo initiated coverage on CareDx with a new price target

      Wells Fargo initiated coverage of CareDx with a rating of Underweight and set a new price target of $28.00

      8/28/24 7:38:28 AM ET
      $CDNA
      Medical Specialities
      Health Care
    • CareDx upgraded by BTIG Research with a new price target

      BTIG Research upgraded CareDx from Neutral to Buy and set a new price target of $40.00

      8/19/24 8:49:21 AM ET
      $CDNA
      Medical Specialities
      Health Care